Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression

No abstract is available for this paper.

• Publication year

  2002

• Venue

  International Clinical Psychopharmacology

• Publication date

  2002-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/00004850-200203000-00001PMID 11890185
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Reboxetine on Anxiety, Agitation, and Insomnia: Results of a Pooled Evaluation of Randomized Clinical Trials

  2002cited by this paper
• Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.

  2000influential reference
• Depressed In-Patients Respond Differently to Imipramine and Mirtazapine

  1999influential reference
• Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.

  1999cited by this paper
• Role of norepinephrine in the pathophysiology and treatment of mood disorders.

  1999cited by this paper
• Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

  1999influential reference
• Antidepressant treatment of the depressed patient with insomnia.

  1999cited by this paper
• Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.

  1999cited by this paper
• Effect of antidepressants on cognitive and psychomotor function: the lack of effect of reboxetine

  1998cited by this paper
• Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression.

  1998influential reference
• Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations

  1998influential reference
• The link between sleep and depression: the effects of antidepressants on EEG sleep.

  1997cited by this paper
• Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.

  1997cited by this paper
• Is there a role for a pure noradrenergic drug in the treatment of depression?

  1997cited by this paper
• Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes

  1997influential reference
• Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.

  1997influential reference
• Comorbid anxious signs and symptoms in major depression: impact on functional work capacity and comparative treatment outcomes

  1993cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• High-performance fluorescence probe for fast and specific visualization of norepinephrine in vivo and depression-like mice.

  2022cites this paper
• A NIR fluorescent probe tracing norepinephrine exocytosis and depression occurrence at the cellular level.

  2022cites this paper
• Kobe University Repository : Kernel タイトル Tit le The Efficacy of Reboxet ine as an Ant idepressant , a Meta-analysis of Both Cont inuous ( Mean HAMD Score ) and Dichotomous ( Response Rate ) Outcomes 著者

  2019cites this paper
• Molecular mechanism of noradrenaline during the stress-induced major depressive disorder

  2018cites this paper
• Understanding the Antidepressant Debate in the Treatment of Major Depressive Disorder.

  2015cites this paper
• Antidepressant effect and toxicity of a new morpholino betalactam compound in male mice

  2014cites this paper
• Antidepressant Medications And Cognitive Functioning In Major Depressive Disorder

  2013cites this paper
• Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with 123I‐INER

  2013cites this paper
• Development of novel radiotracers as tools for imaging the human brain

  2011cites this paper
• Review: reboxetine is ineffective and potentially harmful for acute treatment of major depression

  2011cites this paper
• Comparison of The Efficacy and Safety of Sertraline, Reboxetine, and Venlafaxine in Patients with Major Depressive Disorder: A Pooled Analysis of Four Randomized, Open-Label Trials

  2010cites this paper
• Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

  2010cites this paper
• Current perspectives of the roles of the central norepinephrine system in anxiety and depression

  2010cites this paper
• Missing clinical trial data: setting the record straight

  2010cites this paper
• Milnacipran: a unique antidepressant?

  2010cites this paper
• The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes.

  2008cites this paper
• Psychomotor symptoms in depression: a diagnostic, pathophysiological and therapeutic tool.

  2008cites this paper
• Treating Depression with SNRIs: Who Will Benefit Most?

  2008cites this paper
• The effect of reboxetine in the treatment of depression in children and adolescents

  2007cites this paper
• Hand-Motor Dysfunction in Depression: Characteristics and Pharmacological Effects

  2007cites this paper
• Noradrenergic facilitation of shock-probe defensive burying in lateral septum of rats, and modulation by chronic treatment with desipramine.

  2007cites this paper
• Four-dimensional structure underlying scales for depression anxiety and retardation: emergence of trapped anger and scale improvements.

  2007cites this paper
• Behavior‐dependent modulation of hippocampal EEG activity by the selective norepinephrine reuptake inhibitor reboxetine in rats

  2007cites this paper
• The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.

  2006cites this paper
• Adjunctive atomoxetine for residual fatigue in major depressive disorder.

  2006cites this paper
• Ratings of Early Major Depressive Disorder Symptom Change During a Brief Psychiatric Hospitalization

  2005cites this paper
• What should animal models of depression model?

  2005cites this paper
• Role of brain norepinephrine in the behavioral response to stress.

  2005cites this paper
• Monoaminergic‐based Pharmacotherapy for Depression

  2005cites this paper
• Efficacy and Tolerability of Reboxetine in Depressive Patients Treated in Routine Clinical Practice

  2005cites this paper
• Differential effects of reboxetine and citalopram on hand-motor function in patients suffering from major depression

  2005cites this paper
• Autoreceptor‐mediated inhibition of norepinephrine release in rat medial prefrontal cortex is maintained after chronic desipramine treatment

  2004cites this paper
• Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders.

  2004cites this paper
• Reboxetine: A Norepinephrine Selective Reuptake Pump Inhibitor

  2004cites this paper
• Norepinephrine but not Serotonin Reuptake Inhibitors Enhance Theta and Gamma Activity of the Septo-Hippocampal System

  2003cites this paper
• Current awareness in human psychopharmacology

  2002cites this paper
• Current awareness in human psychopharmacology.

  2002cites this paper
• Akut- und Langzeiteffekte von 3,4-Methylendioxymethamphetamin (MDMA, 'Ecstasy') in Tiermodellen der Sucht und Neurotoxizität

  2002cites this paper
• Neuropsychiatric Disease and Treatment

  year unknowncites this paper